Leap Therapeutics Inc (NASDAQ:LPTX)’s share price hit a new 52-week low on Thursday . The company traded as low as $3.44 and last traded at $3.48, with a volume of 518 shares. The stock had previously closed at $3.68.
Several equities analysts have weighed in on the company. Zacks Investment Research cut Leap Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. HC Wainwright set a $13.00 target price on Leap Therapeutics and gave the company a “buy” rating in a research note on Tuesday, October 23rd. Finally, ValuEngine raised Leap Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 30th.
The company has a market cap of $50.73 million, a price-to-earnings ratio of -0.96 and a beta of 1.99.
Leap Therapeutics (NASDAQ:LPTX) last released its earnings results on Thursday, November 15th. The company reported ($0.45) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.02). Research analysts forecast that Leap Therapeutics Inc will post -2.37 EPS for the current year.
A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Leap Therapeutics by 23.2% during the 3rd quarter. Vanguard Group Inc. now owns 256,268 shares of the company’s stock valued at $1,997,000 after acquiring an additional 48,300 shares in the last quarter. Renaissance Technologies LLC grew its stake in Leap Therapeutics by 23.5% during the 3rd quarter. Renaissance Technologies LLC now owns 138,868 shares of the company’s stock valued at $1,082,000 after acquiring an additional 26,401 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Leap Therapeutics by 178.0% during the 2nd quarter. Point72 Asset Management L.P. now owns 75,888 shares of the company’s stock valued at $683,000 after acquiring an additional 48,588 shares in the last quarter. DRW Securities LLC purchased a new position in Leap Therapeutics during the 2nd quarter valued at about $347,000. Finally, JPMorgan Chase & Co. purchased a new position in Leap Therapeutics during the 3rd quarter valued at about $111,000. 15.52% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/12/08/leap-therapeutics-lptx-reaches-new-52-week-low-at-3-44.html.
Leap Therapeutics Company Profile (NASDAQ:LPTX)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Recommended Story: What is Cost of Debt?
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.